Flutiform Asthma –Drug Forecast and Market Analysis to 2023
Flutiform (Asthma) – Forecast and Market Analysis to 2023: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on sales@marketoptimizer.org with
Flutiform (Asthma) – Forecast and Market Analysis to 2023 in subject line and your contact details.
PharmaPoint Drug Evaluation report, “Flutiform (Asthma) – Forecast and Market Analysis to 2023″. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment.
The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
SkyePharma’s Flutiform is an FDC of fluticasone propionate and formoterol fumarate. Fluticasone propionate is a synthetic corticosteroid with strong anti-inflammatory activity. Fluticasone can bind to glucocorticoid receptors with high affinity and inhibit the secretion of mediators involved in asthma, such as histamine, eicosanoids, leukotrienes, and cytokines. It is three times more potent than budesonide and two times more potent than the active metabolite of beclomethasone dipropionate.
Formoterol fumarate is a LABA that exerts its bronchodilatory activity locally in the lung. LABAs act by stimulating intracellular adenylate cyclase, resulting in increased cAMP levels, which, in turn, cause relaxation of
Flutiform (Asthma) – Forecast and Market Analysis to 2023 in subject line and your contact details.
PharmaPoint Drug Evaluation report, “Flutiform (Asthma) – Forecast and Market Analysis to 2023″. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment.
The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
SkyePharma’s Flutiform is an FDC of fluticasone propionate and formoterol fumarate. Fluticasone propionate is a synthetic corticosteroid with strong anti-inflammatory activity. Fluticasone can bind to glucocorticoid receptors with high affinity and inhibit the secretion of mediators involved in asthma, such as histamine, eicosanoids, leukotrienes, and cytokines. It is three times more potent than budesonide and two times more potent than the active metabolite of beclomethasone dipropionate.
Formoterol fumarate is a LABA that exerts its bronchodilatory activity locally in the lung. LABAs act by stimulating intracellular adenylate cyclase, resulting in increased cAMP levels, which, in turn, cause relaxation of
Bibliography: 7.2 Abbreviations 7.3 Methodology 7.4 Forecasting Methodology 7.4.1 Diagnosed Asthma Patients 7.4.2 Percent Drug-Treated Patients Contact sales@marketoptimizer.org / Call +1 888 391 5441 for further information on “Flutiform (Asthma) – Forecast and Market Analysis to 2023” report OR for any other market research and intelligence needs you may have for your business.